Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Mainz BioMed NV

< Previous 1 2 3 Next >
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
Tickers ASX:MAP MYNZ
Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Secures up to $50M in New Funding
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Expands into Romania Through Partnership with Bioclinica
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Expands Commercial Footprint into Poland
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
From Mainz BioMed NV
Via GlobeNewswire
Tickers ASX:MAP MYNZ
Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed to Participate in Digestive Disease Week 2023
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Provides Full Year 2022 Financial Results
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed to Appear on ClearThink IR’s Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Provides Year-End 2022 Corporate Review
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study
From Mainz BioMed NV
Via GlobeNewswire
Tickers MYNZ
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.